OctoPlus signs service contract with Axentis Pharma

14-Sep-2009 - Netherlands

OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, Axentis Pharma AG. The undisclosed contract value contributes to OctoPlus' annual revenues, for which the Company reiterates its guidance of € 19 million.

Under the contract terms, OctoPlus will perform process development and clinical manufacturing of Axentis Pharma's lead product, which is an inhalable liposomal formulation of tobramycin for the treatment of cystic fibrosis.

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance